Advances in pathogenesis and therapeutic strategies for osteoporosis
- PMID: 35283172
- DOI: 10.1016/j.pharmthera.2022.108168
Advances in pathogenesis and therapeutic strategies for osteoporosis
Abstract
Osteoporosis, is the most common bone disorder worldwide characterized by low bone mineral density, leaving affected bones vulnerable to fracture. Bone homeostasis depends on the precise balance between bone resorption by osteoclasts and bone matrix formation by mesenchymal lineage osteoblasts, and involves a series of complex and highly regulated steps. Bone homeostasis will be disrupted when the speed of bone resorption is faster than bone formation. Based on various regulatory mechanisms of bone homeostasis, a series of drugs targeting osteoporosis have emerged in clinical practice, including bisphosphonates, selective estrogen receptor modulators, calcitonin, molecular-targeted drugs and so on. However, many drugs have major adverse effects or are unsuitable for long-term use. Therefore, it is very urgent to find more effective therapeutic drugs based on the new pathogenesis of osteoporosis. In this review, we summarize novel mechanisms involved in the pathological process of osteoporosis, including the roles of gut microbiome, autophagy, iron balance and cellular senescence. Based on the above pathological mechanism, we found promising drugs for osteoporosis treatment, such as: probiotics, alpha-ketoglutarate, senolytics and hydrogen sulfide. This new finding may provide an important basis for elucidating the complex pathological mechanisms of osteoporosis and provide promising drugs for clinical osteoporosis treatment.
Keywords: Alpha-ketoglutarate; Autophagy; Cellular senescence; Gut microbiome; Hydrogen sulfide; Iron balance; Osteoporosis; Probiotics; Senolytics.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that there are no conflicts of interest with this manuscript.
Similar articles
-
[[Antiresorptive agents in the treatment of osteoporosis].Reumatizam. 2014;61(2):89-94. Reumatizam. 2014. PMID: 25427401 Review. Croatian.
-
[Current topics in drug therapy aiming at bone resorption].Clin Calcium. 2006 Sep;16(9):1475-79. Clin Calcium. 2006. PMID: 16951471 Review. Japanese.
-
Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.Bone. 2014 Feb;59:37-43. doi: 10.1016/j.bone.2013.10.024. Epub 2013 Nov 6. Bone. 2014. PMID: 24211427
-
[Pharmacology of bone resorption inhibitor].Nihon Rinsho. 2015 Oct;73(10):1634-8. Nihon Rinsho. 2015. PMID: 26529923 Japanese.
-
Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.Bone. 1996 Nov;19(5 Suppl):195S-198S. doi: 10.1016/s8756-3282(96)90165-9. Bone. 1996. PMID: 8922662 Review.
Cited by
-
Fructus Ligustri Lucidi inhibits ferroptosis in ovariectomy‑induced osteoporosis in rats via the Nrf2/HO‑1 signaling pathway.Biomed Rep. 2023 Dec 22;20(2):27. doi: 10.3892/br.2023.1715. eCollection 2024 Feb. Biomed Rep. 2023. PMID: 38259585 Free PMC article.
-
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal Transduct Target Ther. 2022 Aug 2;7(1):265. doi: 10.1038/s41392-022-01125-5. Signal Transduct Target Ther. 2022. PMID: 35918332 Free PMC article. Review.
-
Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial.Nutrients. 2023 Apr 21;15(8):2012. doi: 10.3390/nu15082012. Nutrients. 2023. PMID: 37111231 Free PMC article. Clinical Trial.
-
Harnessing hydrogen sulfide in injectable hydrogels that guide the immune response and osteoclastogenesis balance for osteoporosis treatment.Mater Today Bio. 2024 Nov 12;29:101338. doi: 10.1016/j.mtbio.2024.101338. eCollection 2024 Dec. Mater Today Bio. 2024. PMID: 39649246 Free PMC article.
-
Influence of gut microbiome on metabolic diseases: a new perspective based on microgravity.J Diabetes Metab Disord. 2024 Feb 16;23(1):353-364. doi: 10.1007/s40200-024-01394-7. eCollection 2024 Jun. J Diabetes Metab Disord. 2024. PMID: 38932858 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical